Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin and UDCA in Rheumatoid Arthritis
NCT04834557Phase 2Completed
- Sponsor
- Tanta University
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of digoxin and ursodeoxycholic acid in rheumatoid arthritis (RA) (3 arms), sponsored by Tanta University. Primary endpoints: Clinical Disease Activity Index at 24 weeks, C-Reactive Protein at 24 weeks and 1 more. Started Nov 2021; status: completed.
02
Drugs
digoxinursodeoxycholic acid
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04834557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834557.